English

ADAPTIVE BIOTECHNOLOGIES CORPORATION

EDGAR

ADPT Quarterly report (10-Q) · filed 2026-08-04

Annual consolidated revenue for 2025: about USD 277M, using the latest reported figures. The previous period, 2024, was about USD 179M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

71.6 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 71553000 USD Source

Operating margin

-22.04%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -15770000 USD Source
Revenue: 71553000 USD Source

Operating cash flow

-6.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -15937000 USD Source
Operating Cash Flow: -9537000 USD Source

Free cash flow

-7.58 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -15937000 USD Source
Operating Cash Flow: -9537000 USD Source
Capital Expenditure: 1980000 USD Source
Capital Expenditure: 796000 USD Source

Cash and cash equivalents: 170 million USD 2026-06-30 Source
Exact value

169873000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 159 million shares 2026-06-30 Source
Exact value

159059622 shares

Reported share-count change

4.48% · 6.82 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

152234772 shares · 2025-06-30· Source
159059622 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

308 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 93973000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 276976000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 205295000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 70874000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 71553000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-63.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: 9546000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -59499000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -45920000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -20033000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -39788000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-21 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -48041000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -40914000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -45986000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -48041000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -9537000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -15937000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -9537000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

3.03 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 2323000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1914000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2959000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 2323000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 796000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1980000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 796000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-24 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -48041000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -40914000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -45986000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -48041000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -9537000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -15937000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -9537000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 2323000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1914000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2959000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 2323000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 796000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1980000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 796000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-04.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2025-12-31
Total assets: 9 of 11 periods available· newest 2025-12-31
Total liabilities: 9 of 11 periods available· newest 2025-12-31
Current assets: 9 of 11 periods available· newest 2025-12-31
Current liabilities: 9 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+54.8%

Prior period

USD 178.96 million

2024-01-01 – 2024-12-31
Current period

USD 276.98 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

276976000 − 178957000 = 98019000 USD

178957000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
276976000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2025-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Year-over-year change in Revenue: 98019000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 276976000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2508426 Filing: 000119312526076902 Input fundies:Revenue: 178957000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2510206 Filing: 000119312526076902
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 99.99 million

Prior period

−USD 159.49 million

2024-01-01 – 2024-12-31
Current period

−USD 59.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-59499000 − -159492000 = 99993000 USD

-159492000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-59499000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2025-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Year-over-year change in Net income: 99993000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -59499000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#3614639 Filing: 000119312526076902 Input fundies:NetIncome: -159492000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#3616389 Filing: 000119312526076902
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 49.23 million

Prior period

−USD 95.21 million

2024-01-01 – 2024-12-31
Current period

−USD 45.99 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-45986000 − -95212000 = 49226000 USD

-95212000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-45986000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2025-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Year-over-year change in Operating cash flow: 49226000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -45986000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2237283 Filing: 000119312526076902 Input fundies:OperatingCashFlow: -95212000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2239138 Filing: 000119312526076902
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-19.2%

Prior period

USD 3.66 million

2024-01-01 – 2024-12-31
Current period

USD 2.96 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2959000 − 3664000 = -705000 USD

3664000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2959000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2025-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Year-over-year change in Capital expenditure: -705000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2959000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2246774 Filing: 000119312526076902 Input fundies:CapitalExpenditure: 3664000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2248515 Filing: 000119312526076902
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 276.98 million 100% of revenue
Operating costs Derived USD 334.1 million 121% of revenue
Operating income −USD 57.12 million −21% of revenue
Tax, interest and other Derived USD 2.38 million 0.9% of revenue
Net income −USD 59.5 million −21% of revenue

Cash

Operating cash flow −USD 45.99 million −17% of revenue
Capital expenditure USD 2.96 million 1.1% of revenue
Free cash flow Derived −USD 48.95 million −18% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 216% of revenue.
2018 Operating loss: operating costs were 189% of revenue.
2019 Operating loss: operating costs were 192% of revenue.
2020 Operating loss: operating costs were 255% of revenue.
2021 Operating loss: operating costs were 235% of revenue.
2022 Operating loss: operating costs were 208% of revenue.
2023 Operating loss: operating costs were 233% of revenue.
2024 Operating loss: operating costs were 191% of revenue.
2025 Operating loss: operating costs were 121% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	38448000	82923000 Derived	-44475000	-1644000 Derived	-42831000	-37279000 Derived	Source 2017-01-01 – 2017-12-31: 38448000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -44475000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -42831000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -34858000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2421000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	55663000	105419000 Derived	-49756000	-3309000 Derived	-46447000	-38558000 Derived	Source 2018-01-01 – 2018-12-31: 55663000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -49756000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -46447000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -32259000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 6299000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	85071000	163462000 Derived	-78391000	-9785000 Derived	-68606000	194204000 Derived	Source 2019-01-01 – 2019-12-31: 85071000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -78391000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -68606000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 205404000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 11200000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	98382000	251199000 Derived	-152817000	-6590000 Derived	-146227000	-168486000 Derived	Source 2020-01-01 – 2020-12-31: 98382000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -152817000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -146227000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -149683000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 18803000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	154344000	363310000 Derived	-208966000	-1687000 Derived	-207279000	-254473000 Derived	Source 2021-01-01 – 2021-12-31: 154344000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -208966000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -207279000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -192727000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 61746000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	185308000	385494000 Derived	-200186000	5000 Derived	-200191000	-200294000 Derived	Source 2022-01-01 – 2022-12-31: 185308000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -200186000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -200191000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -183945000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 16349000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	170276000	397311000 Derived	-227035000	-1785000 Derived	-225250000	-167021000 Derived	Source 2023-01-01 – 2023-12-31: 170276000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -227035000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -225250000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -156324000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 10697000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	178957000	341506000 Derived	-162549000	-3057000 Derived	-159492000	-98876000 Derived	Source 2024-01-01 – 2024-12-31: 178957000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -162549000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -159492000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -95212000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3664000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	276976000	334099000 Derived	-57123000	2376000 Derived	-59499000	-48945000 Derived	Source 2025-01-01 – 2025-12-31: 276976000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -57123000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -59499000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -45986000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 2959000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 277M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	38448000	Revenue: 38448000 Open source
20182018-12-31	Revenue	55663000	Revenue: 55663000 Open source
20192019-12-31	Revenue	85071000	Revenue: 85071000 Open source
20202020-12-31	Revenue	98382000	Revenue: 98382000 Open source
20212021-12-31	Revenue	154344000	Revenue: 154344000 Open source
20222022-12-31	Revenue	185308000	Revenue: 185308000 Open source
20232023-12-31	Revenue	170276000	Revenue: 170276000 Open source
20242024-12-31	Revenue	178957000	Revenue: 178957000 Open source
20252025-12-31	Revenue	276976000	Revenue: 276976000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

54.8% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 38448000 Open source
20182018-12-31	Year over year	44.8%	Revenue: 55663000 Open source Revenue: 38448000 Open source
20192019-12-31	Year over year	52.8%	Revenue: 85071000 Open source Revenue: 55663000 Open source
20202020-12-31	Year over year	15.6%	Revenue: 98382000 Open source Revenue: 85071000 Open source
20212021-12-31	Year over year	56.9%	Revenue: 154344000 Open source Revenue: 98382000 Open source
20222022-12-31	Year over year	20.1%	Revenue: 185308000 Open source Revenue: 154344000 Open source
20232023-12-31	Year over year	-8.1%	Revenue: 170276000 Open source Revenue: 185308000 Open source
20242024-12-31	Year over year	5.1%	Revenue: 178957000 Open source Revenue: 170276000 Open source
20252025-12-31	Year over year	54.8%	Revenue: 276976000 Open source Revenue: 178957000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -20.6% 2025

Net margin -21.5% 2025

Free cash flow margin -17.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	-115.7%	Operating Income: -44475000 Open source Revenue: 38448000 Open source
20182018-12-31	Operating margin	-89.4%	Operating Income: -49756000 Open source Revenue: 55663000 Open source
20192019-12-31	Operating margin	-92.1%	Operating Income: -78391000 Open source Revenue: 85071000 Open source
20202020-12-31	Operating margin	-155.3%	Operating Income: -152817000 Open source Revenue: 98382000 Open source
20212021-12-31	Operating margin	-135.4%	Operating Income: -208966000 Open source Revenue: 154344000 Open source
20222022-12-31	Operating margin	-108%	Operating Income: -200186000 Open source Revenue: 185308000 Open source
20232023-12-31	Operating margin	-133.3%	Operating Income: -227035000 Open source Revenue: 170276000 Open source
20242024-12-31	Operating margin	-90.8%	Operating Income: -162549000 Open source Revenue: 178957000 Open source
20252025-12-31	Operating margin	-20.6%	Operating Income: -57123000 Open source Revenue: 276976000 Open source
20172017-12-31	Net margin	-111.4%	Net Income: -42831000 Open source Revenue: 38448000 Open source
20182018-12-31	Net margin	-83.4%	Net Income: -46447000 Open source Revenue: 55663000 Open source
20192019-12-31	Net margin	-80.6%	Net Income: -68606000 Open source Revenue: 85071000 Open source
20202020-12-31	Net margin	-148.6%	Net Income: -146227000 Open source Revenue: 98382000 Open source
20212021-12-31	Net margin	-134.3%	Net Income: -207279000 Open source Revenue: 154344000 Open source
20222022-12-31	Net margin	-108%	Net Income: -200191000 Open source Revenue: 185308000 Open source
20232023-12-31	Net margin	-132.3%	Net Income: -225250000 Open source Revenue: 170276000 Open source
20242024-12-31	Net margin	-89.1%	Net Income: -159492000 Open source Revenue: 178957000 Open source
20252025-12-31	Net margin	-21.5%	Net Income: -59499000 Open source Revenue: 276976000 Open source
20172017-12-31	Free cash flow margin	-97%	Revenue: 38448000 Open source Operating Cash Flow: -34858000 Open source Capital Expenditure: 2421000 Open source
20182018-12-31	Free cash flow margin	-69.3%	Revenue: 55663000 Open source Operating Cash Flow: -32259000 Open source Capital Expenditure: 6299000 Open source
20192019-12-31	Free cash flow margin	228.3%	Revenue: 85071000 Open source Operating Cash Flow: 205404000 Open source Capital Expenditure: 11200000 Open source
20202020-12-31	Free cash flow margin	-171.3%	Revenue: 98382000 Open source Operating Cash Flow: -149683000 Open source Capital Expenditure: 18803000 Open source
20212021-12-31	Free cash flow margin	-164.9%	Revenue: 154344000 Open source Operating Cash Flow: -192727000 Open source Capital Expenditure: 61746000 Open source
20222022-12-31	Free cash flow margin	-108.1%	Revenue: 185308000 Open source Operating Cash Flow: -183945000 Open source Capital Expenditure: 16349000 Open source
20232023-12-31	Free cash flow margin	-98.1%	Revenue: 170276000 Open source Operating Cash Flow: -156324000 Open source Capital Expenditure: 10697000 Open source
20242024-12-31	Free cash flow margin	-55.3%	Revenue: 178957000 Open source Operating Cash Flow: -95212000 Open source Capital Expenditure: 3664000 Open source
20252025-12-31	Free cash flow margin	-17.7%	Revenue: 276976000 Open source Operating Cash Flow: -45986000 Open source Capital Expenditure: 2959000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -46M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	-34858000	Operating Cash Flow: -34858000 Open source
20182018-12-31	Operating cash flow	-32259000	Operating Cash Flow: -32259000 Open source
20192019-12-31	Operating cash flow	205404000	Operating Cash Flow: 205404000 Open source
20202020-12-31	Operating cash flow	-149683000	Operating Cash Flow: -149683000 Open source
20212021-12-31	Operating cash flow	-192727000	Operating Cash Flow: -192727000 Open source
20222022-12-31	Operating cash flow	-183945000	Operating Cash Flow: -183945000 Open source
20232023-12-31	Operating cash flow	-156324000	Operating Cash Flow: -156324000 Open source
20242024-12-31	Operating cash flow	-95212000	Operating Cash Flow: -95212000 Open source
20252025-12-31	Operating cash flow	-45986000	Operating Cash Flow: -45986000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -48.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	-37279000	Operating Cash Flow: -34858000 Open source Capital Expenditure: 2421000 Open source
20182018-12-31	Free cash flow	-38558000	Operating Cash Flow: -32259000 Open source Capital Expenditure: 6299000 Open source
20192019-12-31	Free cash flow	194204000	Operating Cash Flow: 205404000 Open source Capital Expenditure: 11200000 Open source
20202020-12-31	Free cash flow	-168486000	Operating Cash Flow: -149683000 Open source Capital Expenditure: 18803000 Open source
20212021-12-31	Free cash flow	-254473000	Operating Cash Flow: -192727000 Open source Capital Expenditure: 61746000 Open source
20222022-12-31	Free cash flow	-200294000	Operating Cash Flow: -183945000 Open source Capital Expenditure: 16349000 Open source
20232023-12-31	Free cash flow	-167021000	Operating Cash Flow: -156324000 Open source Capital Expenditure: 10697000 Open source
20242024-12-31	Free cash flow	-98876000	Operating Cash Flow: -95212000 Open source Capital Expenditure: 3664000 Open source
20252025-12-31	Free cash flow	-48945000	Operating Cash Flow: -45986000 Open source Capital Expenditure: 2959000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

56.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Liabilities / assets	7.1%	Total Liabilities: 25772000 Open source Total Assets: 362489000 Open source
20182018-12-31	Liabilities / assets	9%	Total Liabilities: 29942000 Open source Total Assets: 332688000 Open source
20192019-12-31	Liabilities / assets	37.4%	Total Liabilities: 341263000 Open source Total Assets: 912302000 Open source
20202020-12-31	Liabilities / assets	33.4%	Total Liabilities: 373148000 Open source Total Assets: 1116414000 Open source
20212021-12-31	Liabilities / assets	34.6%	Total Liabilities: 319242000 Open source Total Assets: 923344000 Open source
20222022-12-31	Liabilities / assets	45.8%	Total Liabilities: 392519000 Open source Total Assets: 856617000 Open source
20232023-12-31	Liabilities / assets	53.4%	Total Liabilities: 352856000 Open source Total Assets: 661134000 Open source
20242024-12-31	Liabilities / assets	62.5%	Total Liabilities: 336891000 Open source Total Assets: 539376000 Open source
20252025-12-31	Liabilities / assets	56.1%	Total Liabilities: 287735000 Open source Total Assets: 512736000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.34× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Current assets / current liabilities	9.77×	Current Assets: 205247000 Open source Current Liabilities: 21003000 Open source
20182018-12-31	Current assets / current liabilities	7.93×	Current Assets: 180718000 Open source Current Liabilities: 22800000 Open source
20192019-12-31	Current assets / current liabilities	7.82×	Current Assets: 612690000 Open source Current Liabilities: 78313000 Open source
20202020-12-31	Current assets / current liabilities	6.91×	Current Assets: 726914000 Open source Current Liabilities: 105197000 Open source
20212021-12-31	Current assets / current liabilities	3.54×	Current Assets: 402748000 Open source Current Liabilities: 113807000 Open source
20222022-12-31	Current assets / current liabilities	5.12×	Current Assets: 562146000 Open source Current Liabilities: 109788000 Open source
20232023-12-31	Current assets / current liabilities	4.66×	Current Assets: 410188000 Open source Current Liabilities: 88015000 Open source
20242024-12-31	Current assets / current liabilities	2.89×	Current Assets: 283752000 Open source Current Liabilities: 98053000 Open source
20252025-12-31	Current assets / current liabilities	3.34×	Current Assets: 300185000 Open source Current Liabilities: 89915000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 42.83 million Exact value Exact value: -42831000 USD 2017-01-01 – 2017-12-31: -42831000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2017-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -42831000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42831000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459020006830/adpt-10k_20191231.htm#4342525 Filing: 000156459020006830 The citation records this snapshot. The page link may show a newer release later.	−USD 34.86 million Exact value Exact value: -34858000 USD 2017-01-01 – 2017-12-31: -34858000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2017-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: -34858000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34858000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459020006830/adpt-10k_20191231.htm#3049172 Filing: 000156459020006830 The citation records this snapshot. The page link may show a newer release later.	USD 2.42 million Exact value Exact value: 2421000 USD 2017-01-01 – 2017-12-31: 2421000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2017-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 2421000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2421000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459020006830/adpt-10k_20191231.htm#3060199 Filing: 000156459020006830 The citation records this snapshot. The page link may show a newer release later.	−USD 37.28 million Calculation and evidence -34858000 − 2421000 USD Exact free cash flow: -37279000 USD 2017-01-01 – 2017-12-31: -34858000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2421000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2017-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: -37279000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34858000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459020006830/adpt-10k_20191231.htm#3049172 Filing: 000156459020006830 Input fundies:CapitalExpenditure: 2421000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459020006830/adpt-10k_20191231.htm#3060199 Filing: 000156459020006830 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 46.45 million Exact value Exact value: -46447000 USD 2018-01-01 – 2018-12-31: -46447000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2018-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -46447000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -46447000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-10k_20201231.htm#4022470 Filing: 000156459021008124 The citation records this snapshot. The page link may show a newer release later.	−USD 32.26 million Exact value Exact value: -32259000 USD 2018-01-01 – 2018-12-31: -32259000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2018-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: -32259000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32259000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-10k_20201231.htm#2766170 Filing: 000156459021008124 The citation records this snapshot. The page link may show a newer release later.	USD 6.3 million Exact value Exact value: 6299000 USD 2018-01-01 – 2018-12-31: 6299000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2018-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 6299000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6299000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-10k_20201231.htm#2777198 Filing: 000156459021008124 The citation records this snapshot. The page link may show a newer release later.	−USD 38.56 million Calculation and evidence -32259000 − 6299000 USD Exact free cash flow: -38558000 USD 2018-01-01 – 2018-12-31: -32259000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 6299000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2018-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: -38558000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32259000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-10k_20201231.htm#2766170 Filing: 000156459021008124 Input fundies:CapitalExpenditure: 6299000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-10k_20201231.htm#2777198 Filing: 000156459021008124 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 68.61 million Exact value Exact value: -68606000 USD 2019-01-01 – 2019-12-31: -68606000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2019-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -68606000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68606000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005228/adpt-10k_20211231.htm#3963044 Filing: 000156459022005228 The citation records this snapshot. The page link may show a newer release later.	USD 205.4 million Exact value Exact value: 205404000 USD 2019-01-01 – 2019-12-31: 205404000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2019-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: 205404000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 205404000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005228/adpt-10k_20211231.htm#2732707 Filing: 000156459022005228 The citation records this snapshot. The page link may show a newer release later.	USD 11.2 million Exact value Exact value: 11200000 USD 2019-01-01 – 2019-12-31: 11200000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2019-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 11200000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11200000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005228/adpt-10k_20211231.htm#2743750 Filing: 000156459022005228 The citation records this snapshot. The page link may show a newer release later.	USD 194.2 million Calculation and evidence 205404000 − 11200000 USD Exact free cash flow: 194204000 USD 2019-01-01 – 2019-12-31: 205404000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 11200000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2019-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: 194204000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 205404000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005228/adpt-10k_20211231.htm#2732707 Filing: 000156459022005228 Input fundies:CapitalExpenditure: 11200000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005228/adpt-10k_20211231.htm#2743750 Filing: 000156459022005228 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 146.23 million Exact value Exact value: -146227000 USD 2020-01-01 – 2020-12-31: -146227000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2020-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -146227000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -146227000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-20221231.htm#4343034 Filing: 000095017023002792 The citation records this snapshot. The page link may show a newer release later.	−USD 149.68 million Exact value Exact value: -149683000 USD 2020-01-01 – 2020-12-31: -149683000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2020-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: -149683000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -149683000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-20221231.htm#2855357 Filing: 000095017023002792 The citation records this snapshot. The page link may show a newer release later.	USD 18.8 million Exact value Exact value: 18803000 USD 2020-01-01 – 2020-12-31: 18803000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2020-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 18803000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18803000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-20221231.htm#2866715 Filing: 000095017023002792 The citation records this snapshot. The page link may show a newer release later.	−USD 168.49 million Calculation and evidence -149683000 − 18803000 USD Exact free cash flow: -168486000 USD 2020-01-01 – 2020-12-31: -149683000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 18803000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2020-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: -168486000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -149683000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-20221231.htm#2855357 Filing: 000095017023002792 Input fundies:CapitalExpenditure: 18803000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-20221231.htm#2866715 Filing: 000095017023002792 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 207.28 million Exact value Exact value: -207279000 USD 2021-01-01 – 2021-12-31: -207279000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2021-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -207279000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -207279000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017024023095/adpt-20231231.htm#2867615 Filing: 000095017024023095 The citation records this snapshot. The page link may show a newer release later.	−USD 192.73 million Exact value Exact value: -192727000 USD 2021-01-01 – 2021-12-31: -192727000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2021-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: -192727000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -192727000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017024023095/adpt-20231231.htm#1879251 Filing: 000095017024023095 The citation records this snapshot. The page link may show a newer release later.	USD 61.75 million Exact value Exact value: 61746000 USD 2021-01-01 – 2021-12-31: 61746000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2021-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 61746000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 61746000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017024023095/adpt-20231231.htm#1886049 Filing: 000095017024023095 The citation records this snapshot. The page link may show a newer release later.	−USD 254.47 million Calculation and evidence -192727000 − 61746000 USD Exact free cash flow: -254473000 USD 2021-01-01 – 2021-12-31: -192727000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 61746000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2021-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: -254473000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -192727000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017024023095/adpt-20231231.htm#1879251 Filing: 000095017024023095 Input fundies:CapitalExpenditure: 61746000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017024023095/adpt-20231231.htm#1886049 Filing: 000095017024023095 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 200.19 million Exact value Exact value: -200191000 USD 2022-01-01 – 2022-12-31: -200191000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2022-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -200191000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -200191000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017025030913/adpt-20241231.htm#3777904 Filing: 000095017025030913 The citation records this snapshot. The page link may show a newer release later.	−USD 183.95 million Exact value Exact value: -183945000 USD 2022-01-01 – 2022-12-31: -183945000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2022-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: -183945000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -183945000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017025030913/adpt-20241231.htm#2209098 Filing: 000095017025030913 The citation records this snapshot. The page link may show a newer release later.	USD 16.35 million Exact value Exact value: 16349000 USD 2022-01-01 – 2022-12-31: 16349000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2022-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 16349000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 16349000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017025030913/adpt-20241231.htm#2217720 Filing: 000095017025030913 The citation records this snapshot. The page link may show a newer release later.	−USD 200.29 million Calculation and evidence -183945000 − 16349000 USD Exact free cash flow: -200294000 USD 2022-01-01 – 2022-12-31: -183945000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 16349000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2022-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: -200294000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -183945000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017025030913/adpt-20241231.htm#2209098 Filing: 000095017025030913 Input fundies:CapitalExpenditure: 16349000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000095017025030913/adpt-20241231.htm#2217720 Filing: 000095017025030913 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 225.25 million Exact value Exact value: -225250000 USD 2023-01-01 – 2023-12-31: -225250000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2023-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -225250000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -225250000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#3618137 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	−USD 156.32 million Exact value Exact value: -156324000 USD 2023-01-01 – 2023-12-31: -156324000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2023-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: -156324000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -156324000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2240993 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	USD 10.7 million Exact value Exact value: 10697000 USD 2023-01-01 – 2023-12-31: 10697000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2023-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 10697000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10697000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2250256 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	−USD 167.02 million Calculation and evidence -156324000 − 10697000 USD Exact free cash flow: -167021000 USD 2023-01-01 – 2023-12-31: -156324000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 10697000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2023-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: -167021000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -156324000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2240993 Filing: 000119312526076902 Input fundies:CapitalExpenditure: 10697000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2250256 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 159.49 million Exact value Exact value: -159492000 USD 2024-01-01 – 2024-12-31: -159492000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2024-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -159492000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -159492000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#3616389 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	−USD 95.21 million Exact value Exact value: -95212000 USD 2024-01-01 – 2024-12-31: -95212000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2024-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: -95212000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -95212000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2239138 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	USD 3.66 million Exact value Exact value: 3664000 USD 2024-01-01 – 2024-12-31: 3664000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2024-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 3664000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3664000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2248515 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	−USD 98.88 million Calculation and evidence -95212000 − 3664000 USD Exact free cash flow: -98876000 USD 2024-01-01 – 2024-12-31: -95212000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3664000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2024-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: -98876000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -95212000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2239138 Filing: 000119312526076902 Input fundies:CapitalExpenditure: 3664000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2248515 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 59.5 million Exact value Exact value: -59499000 USD 2025-01-01 – 2025-12-31: -59499000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2025-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Net Income: -59499000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -59499000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#3614639 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	−USD 45.99 million Exact value Exact value: -45986000 USD 2025-01-01 – 2025-12-31: -45986000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2025-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Operating Cash Flow: -45986000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45986000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2237283 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	USD 2.96 million Exact value Exact value: 2959000 USD 2025-01-01 – 2025-12-31: 2959000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2025-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Capital Expenditure: 2959000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2959000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2246774 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.	−USD 48.95 million Calculation and evidence -45986000 − 2959000 USD Exact free cash flow: -48945000 USD 2025-01-01 – 2025-12-31: -45986000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 2959000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ADAPTIVE BIOTECHNOLOGIES CORPORATION · 2025-12-31 ADAPTIVE BIOTECHNOLOGIES CORPORATION (edgar:1478320) Free cash flow: -48945000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:11:22Z Snapshot: da5d3122fde4344d7ba2733ccff7a1cb2dd96ec5e707d98e9110f3642023fab9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1478320?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45986000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2237283 Filing: 000119312526076902 Input fundies:CapitalExpenditure: 2959000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm#2246774 Filing: 000119312526076902 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

45 filings · 2,536 latest values · 2,536 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001478320, 1478320, ADPT, edgar:1478320

Also known as ADAPTIVE BIOTECHNOLOGIES CORPORATION, Adaptive Biotechnologies Corp, Adaptive TCR Corp

ADAPTIVE BIOTECHNOLOGIES CORPORATION

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation